The Role for Vitamin and Mineral Supplements in Diabetes Management

D. Enette Larson-Meyer, PhD, RD, FACSM Saturday, February 18, 2017 11:30 a.m. – 12:15 p.m.

The American Diabetes Association Standards of Medical Care currently do not support the widespread use of vitamin and mineral supplements for diabetes management because of the lack of sufficient evidence. Cumulative evidence, however, suggests that supplementation with some vitamins and minerals has the potential to improve glycemic control, and macro- and microvascular complications in at least in some patients. This presentation will review key nutrients that may play a role in diabetes management including chromium, magnesium, vanadium, biotin, vitamins C, D, E and B12, and the scientific evidence supporting (or not supporting) their use either in supplemental doses or as part of a healthful diet and lifestyle pattern.

References:

- 1. American Diabetes A. Standards of medical care in diabetes--2014. Diabetes Care 2014; 37 Suppl 1: S14-80.
- 2. Balk EM, Tatsioni A, Lichtenstein AH et al. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care 2007; 30: 2154-63.
- 3. Schwarz K, Mertz W. Chromium(III) and the glucose tolerance factor. Arch Biochem Biophys 1959; 85: 292-5.
- 4. Suksomboon N, Poolsup N, Yuwanakorn A. Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. J Clin Pharm Ther 2014; 39: 292-306.
- 5. National Institute of Health. Office of Dietary Supplements. Chromium: Dietary Supplements Fact sheet available at https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/. 2013 (online).
- 6. Wang ZQ, Cefalu WT. Current concepts about chromium supplementation in type 2 diabetes and insulin resistance. Curr Diab Rep 2010; 10: 145-51.
- 7. Yin RV, Phung OJ. Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus. Nutr J 2015; 14: 14.
- 8. Albarracin C, Fuqua B, Geohas J et al. Combination of chromium and biotin improves coronary risk factors in hypercholesterolemic type 2 diabetes mellitus: a placebo-controlled, double-blind randomized clinical trial. J Cardiometab Syndr 2007; 2: 91-7.
- 9. Albarracin CA, Fuqua BC, Evans JL, Goldfine ID. Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev 2008; 24: 41-51.
- 10. Singer GM, Geohas J. The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: a placebocontrolled, double-blinded, randomized trial. Diabetes Technol Ther 2006; 8: 636-43.
- 11. de Paula TP, Kramer CK, Viana LV, Azevedo MJ. Effects of individual micronutrients on blood pressure in patients with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. Sci Rep 2017; 7: 40751.
- 12. Dong JY, Xun P, He K, Qin LQ. Magnesium intake and risk of type 2 diabetes: metaanalysis of prospective cohort studies. Diabetes Care 2011; 34: 2116-22.
- 13. Guerrero-Romero F, Rodriguez-Moran M. The effect of lowering blood pressure by magnesium supplementation in diabetic hypertensive adults with low serum magnesium

levels: a randomized, double-blind, placebo-controlled clinical trial. J Hum Hypertens 2009; 23: 245-51.

- 14. Hruby A, Ngwa JS, Renstrom F et al. Higher magnesium intake is associated with lower fasting glucose and insulin, with no evidence of interaction with select genetic loci, in a meta-analysis of 15 CHARGE Consortium Studies. J Nutr 2013; 143: 345-53.
- 15. Sales CH, Pedrosa LF, Lima JG et al. Influence of magnesium status and magnesium intake on the blood glucose control in patients with type 2 diabetes. Clin Nutr 2011; 30: 359-64.
- 16. Song Y, He K, Levitan EB et al. Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabet Med 2006; 23: 1050-6.
- 17. Veronese N, Watutantrige-Fernando S, Luchini C et al. Effect of magnesium supplementation on glucose metabolism in people with or at risk of diabetes: a systematic review and meta-analysis of double-blind randomized controlled trials. Eur J Clin Nutr 2016; 70: 1354-9.
- 18. Khodaeian M, Tabatabaei-Malazy O, Qorbani M et al. Effect of vitamins C and E on insulin resistance in diabetes: a meta-analysis study. Eur J Clin Invest 2015; 45: 1161-74.
- 19. Myung SK, Ju W, Cho B et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2013; 346: f10.
- 20. Suksomboon N, Poolsup N, Sinprasert S. Effects of vitamin E supplementation on glycaemic control in type 2 diabetes: systematic review of randomized controlled trials. J Clin Pharm Ther 2011; 36: 53-63.
- 21. Xu R, Zhang S, Tao A et al. Influence of vitamin E supplementation on glycaemic control: a meta-analysis of randomised controlled trials. PLoS One 2014; 9: e95008.
- 22. Jin L, Xue HY, Jin LJ et al. Antioxidant and pancreas-protective effect of aucubin on rats with streptozotocin-induced diabetes. Eur J Pharmacol 2008; 582: 162-7.
- 23. Krul-Poel YH, Ter Wee MM, Lips P, Simsek S. MANAGEMENT OF ENDOCRINE DISEASE: The effect of vitamin D supplementation on glycaemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Eur J Endocrinol 2017; 176: R1-R14.
- 24. Will JC, Byers T. Does diabetes mellitus increase the requirement for vitamin C? Nutr Rev 1996; 54: 193-202.
- 25. Tabatabaei-Malazy O, Nikfar S, Larijani B, Abdollahi M. Influence of ascorbic acid supplementation on type 2 diabetes mellitus in observational and randomized controlled trials; a systematic review with meta-analysis. J Pharm Pharm Sci 2014; 17: 554-82.
- 26. Cusi K, Cukier S, DeFronzo RA et al. Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 1410-7.
- 27. Jacques-Camarena O, Gonzalez-Ortiz M, Martinez-Abundis E et al. Effect of vanadium on insulin sensitivity in patients with impaired glucose tolerance. Ann Nutr Metab 2008; 53: 195-8.
- 28. Pandey SK, Anand-Srivastava MB, Srivastava AK. Vanadyl sulfate-stimulated glycogen synthesis is associated with activation of phosphatidylinositol 3-kinase and is independent of insulin receptor tyrosine phosphorylation. Biochemistry 1998; 37: 7006-14.
- 29. Smith DM, Pickering RM, Lewith GT. A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus. QJM 2008; 101: 351-8.
- 30. Thompson KH, Orvig C. Vanadium in diabetes: 100 years from Phase 0 to Phase I. J Inorg Biochem 2006; 100: 1925-35.

- 31. Verma S, Cam MC, McNeill JH. Nutritional factors that can favorably influence the glucose/insulin system: vanadium. J Am Coll Nutr 1998; 17: 11-8.
- 32. Bouillon R, Carmeliet G, Verlinden L et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726-76.
- 33. Chagas CE, Borges MC, Martini LA, Rogero MM. Focus on vitamin D, inflammation and type 2 diabetes. Nutrients 2012; 4: 52-67.
- 34. George PS, Pearson ER, Witham MD. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. Diabet Med 2012; 29: e142-50.
- 35. Grammatiki M, Rapti E, Karras S et al. Vitamin D and diabetes mellitus: Causal or casual association? Rev Endocr Metab Disord 2017.
- 36. Hoffmann MR, Senior PA, Mager DR. Vitamin D supplementation and health-related quality of life: a systematic review of the literature. J Acad Nutr Diet 2015; 115: 406-18.
- 37. Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-30.
- Larson-Meyer DE, Willis KS. Vitamin D and athletes. Curr Sports Med Rep 2010; 9: 220-6.
- 39. Poolsup N, Suksomboon N, Plordplong N. Effect of vitamin D supplementation on insulin resistance and glycaemic control in prediabetes: a systematic review and meta-analysis. Diabet Med 2016; 33: 290-9.
- 40. Seida JC, Mitri J, Colmers IN et al. Clinical review: Effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2014; 99: 3551-60.
- 41. Shore-Lorenti C, Brennan SL, Sanders KM et al. Shining the light on Sunshine: a systematic review of the influence of sun exposure on type 2 diabetes mellitus-related outcomes. Clin Endocrinol (Oxf) 2014; 81: 799-811.
- 42. Herrmann M, Sullivan DR, Veillard AS et al. Serum 25-hydroxyvitamin D: a predictor of macrovascular and microvascular complications in patients with type 2 diabetes. Diabetes Care 2015; 38: 521-8.
- 43. Lee P, Chen R. Vitamin D as an analgesic for patients with type 2 diabetes and neuropathic pain. Arch Intern Med 2008; 168: 771-2.
- 44. Shehab D, Al-Jarallah K, Abdella N et al. Prospective evaluation of the effect of shortterm oral vitamin d supplementation on peripheral neuropathy in type 2 diabetes mellitus. Med Princ Pract 2015; 24: 250-6.
- 45. Haeusler S, Parry-Strong A, Krebs JD. The prevalence of low vitamin B12 status in people with type 2 diabetes receiving metformin therapy in New Zealand--a clinical audit. N Z Med J 2014; 127: 8-16.
- 46. Liu Q, Li S, Quan H, Li J. Vitamin B12 status in metformin treated patients: systematic review. PLoS One 2014; 9: e100379.
- 47. Parry-Strong A, Langdana F, Haeusler S et al. Sublingual vitamin B12 compared to intramuscular injection in patients with type 2 diabetes treated with metformin: a randomised trial. N Z Med J 2016; 129: 67-75.
- 48. Sun Y, Lai MS, Lu CJ. Effectiveness of vitamin B12 on diabetic neuropathy: systematic review of clinical controlled trials. Acta Neurol Taiwan 2005; 14: 48-54.
- 49. Talaei A, Siavash M, Majidi H, Chehrei A. Vitamin B12 may be more effective than nortriptyline in improving painful diabetic neuropathy. Int J Food Sci Nutr 2009; 60 Suppl 5: 71-6.
- 50. Barringer TA, Kirk JK, Santaniello AC et al. Effect of a multivitamin and mineral supplement on infection and quality of life. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138: 365-71.


- 51. Gunasekara P, Hettiarachchi M, Liyanage C, Lekamwasam S. Effects of zinc and multimineral vitamin supplementation on glycemic and lipid control in adult diabetes. Diabetes Metab Syndr Obes 2011; 4: 53-60.
- 52. Valdes-Ramos R, Guadarrama-Lopez AL, Martinez-Carrillo BE, Benitez-Arciniega AD. Vitamins and type 2 diabetes mellitus. Endocr Metab Immune Disord Drug Targets 2015; 15: 54-63.


The Role for Vitamin and Mineral Supplements in Diabetes Management D. Enette Larson-Meyer, PhD, RD, CSSD, FACSM


Disclosures

no financial conflicts of interest











PURPORTED FUNCTION IN DIABETES:

- ▶ Deficiency results in insulin resistance & diabetes 🖕 Animal studies, TPN cases
- \uparrow #insulin receptors, \uparrow insulin binding at action site, \uparrow receptor signaling (via chromodulin), ↓protein-tyrosine phosphatase 1B
- z & Mertz, Arch Biochem Biophys, 1959. of Medicine, 2006, Wang and Cefalu Curr Diab I

Chromium

STUDIES


▶ Over 200 human studies → ~28 RCT


5 meta-analyses evaluating effect of supplementation on DM management (2002, 2007, 2010, 2014*, 2015)

DOSING: 150 -1000 $\mu\text{g}/\text{day}$ as $\text{CrCl}_3,$ Cr Picolinate (salt), Cr-yeast or Brewers Yeast (1.28 to 42 µg day) for 3 to 24 w

RESULTS*:

- ▶ Improvement in HbA1c (↓ 0.55 0.88%) → better with CrPic (↓ 0.6 %, CI=1.06-0.15%). Doses >200 µg/d for >3 wk needed; better response in those with HbA1c >8% (14 studies)
- ▶ Reduction in FPG with CrPic (↓23.4 mg/dL, CI=1.97-0.30) and Brewers Yeast (24 studies) Improvement in TG (150 mg/dL) and HDL (14.6 mg/dL) with CrPic; No impact on Total-
- and LDL-Cholesterol (15 studies) *Suksomboon et al, J Clin Pharm Ther 2014, Yin & Phung, Nutr J, 2015





24

Cr

52.00

- Supplementation for <3 weeks not effective (e.g., half-life of RBC)</p>
- Some evidence CrPic may be adjuvant therapy for certain subgroups of patients (HbA1c >8%[†]FPG) who are not on specific medications)

ksomboon et al, J Clin Pharm Ther 2014, NIH Office of Dietary Supplements, Wang and Cefalu Curr Diab Rep 2010

Modulates glucokinase activity → suppresses hepatic glucose output & gluconeogenesis (limits phospoenolpyruvate carboxykinase)

 Acts synergistically with chromium to enhance glucose uptake (pre-clinical) McCarty, Med Hypothesis 1999, Singer Diabetes Techinol Ther 2006





24

Biotin plus Chromium

STUDIES:

Pilot study* and several RCT** of Biotin plus Chromium Picolinate

DOSING: 2 mg biotin/day plus 600 µg *CrPic/day for 28-90 days

RESULTS:

- Combined supplementation improved HbAlc (\$0.53%) and FPG (\$9.5 mg/dL) in patients with T2DM (n=226 poorly control DM on antidiabetic therapy) vs placebo (n=122)**, and improved glucose response following OGTT (\$0.7% \$AIC) (n=43)*
- Supplementation improved serum lipids in patients with high cholesterol (total cholesterol ↓9 mg/dl and LDL ↓22 mg/dl) with some influence on TG
- Studies have not look at combined supplementation vs biotin and chromium alone

"Singer Diabetes Techinol Ther 2006, *"Albarracin et al J Cardiometabolic Synd 2007, Diabetes Metab Res Rev 2008

Biotin plus Chromium

- SIDE EFFECTS -previously mentioned for chromium:
- Risk of adverse advents no different than placebo but long-term safety not known Patients with preexisting renal or liver disease more susceptible to adverse effects of chromium
- Cr supplementation can interfere with some medications

CLINICAL IMPLICATIONS:

- $2~mg/day~plus~600~\mu g/day~^{CrPic}$ for ~28-90 days may be effective at improving HbA1c and FPG
- Combo may be an effective adjunctive nutritional therapy for those with poorly controlled diabetes with the potential for improving lipid metabolism
- However, more research needed; Evidence limited to few RCTs.

* Suksomboon et al J Clin Pharm Ther 2014 , Albarracin et al J Cardiometabolic Synd 2007, Diabetes Metab Res Rev 2008

Magnesium



agents with diarrhea as

12

Mg

24.305

endpoint

FUNCTION:

- Cofactor in over 300 metabolic reactions
- Intracellular calcium & potassium homeostasis

SOURCES: Green leafy vegetables, legumes, whole grains, nuts & seeds; milk, meat (med) Absorption ~50% but high phytates, fiber and phosphates↓ *UL based on pharmacological



PURPORTED FUNCTION IN DIABETES:

- Mg cofactor in phosphorylation & dephosphorylation reactions in glycolysis (MnATP²⁺⁾
- Mg deficiency strongly related to insulin resistance
- Protein kinases in insulin signaling cascade and insulin secretion Mg-dependent
- ➡ ↑risk Mg status and/or intake commonly decreased in patients with diabetes

Sales et al, Clinical Nutr 2011, Hruby et al, J Nutr 2013, Dong et al, Diabetes Care, 2011, Veronese et al Eur J Clin Nutr 201

Magnesium STUDIES

Several targeted meta-analyses of supplementation on glycemic control and blood pressure in patients with diabetes or at risk for diabetes (2006, 2016, 2016) Recent meta-analysis of 12 RCT in patients with Diabetes and 6 RCT in those at risk

12

Mg

DOSING: Various doses/forms, e.g., 360 - 450 mg/day

RESULTS:

- patients at risk for diabetes (FPG (19.4 mg/dL)
- No improvement in HbAlc in patients with T2DM
- Improved glucose response after OGTT (2 hr), and trend for improved IR (HOMA) in patients at risk for DM
- **related to change in serum Mg**
- Reduction in systolic (120.4 mmHg) and diastolic (18.7 mmHg) blood pressure with 4 mo supplementation Song et al Diabet Med, 2006, De Paula et al, Sci Rep 2017, Guerrero-Romero Rodriguez-Moran, J Hum Hypertens 2009, Veronese et al Eur J Clin Nutr 201

Magnesium


SIDE EFFECTS:

- Iow pharmacological doses known to cause nausea, abdominal cramps, diarrhea RCTs did not find evidence of severe side effects.
- $\blacktriangleright\,$ Pharmacological doses $\rightarrow\,$ can cause metabolic hypokalemia, paralytic ileus Hypermagnesemia possible in those with renal insufficiency or taking Mg-containing Meds

CLINICAL IMPLICATIONS:

- Suggestive benefit of magnesium supplementation on improving glucose parameters and blood pressure in diabetic patients, and insulin-sensitivity parameters in those at risk for diabetes who have low magnesium status \rightarrow additional studies needed*
- Magnesium supplementation is well tolerated and is attracting interest in diabetes management, little is known about optimal dose and preparation'
- Benefit to maintaining magnesium status through diet high in minimally-processed foods with selective supplementation to maintain normal status.

et al, Clinical Nutr 2011, Guerroro-Romero & Rodriguez-Moran J Hum Hypertens 2009,



Jin et al, Eur J Pharmacol 2008, Myung et al, BMJ 2013

Vitamin E

STUDIES:

- Two recent meta-analyses evaluating effect of supplementation on insulin resistance and glycemic control
 - 8 RCT in 425 patients with T2DM/controls evaluating insulin resistance (HOMA-IR)
 - ▶ 14 RCT in 363 patients (mostly with T2DM) evaluating glycemic control

DOSING: 150- 800 mg/day / 200 - 1600 IU for 4 to 27 weeks (^ ^ RDA)


RESULTS:

- Supplementation did not improve HOMA-IR but authors concluded "non statistical improvement in insulin resistance"
- Supplementation did not improve HbA1c, FPG or fasting insulin overall.
- However, reduction in HbA1c and fasting insulin found in patients with low Vit E status (\downarrow 0.58%, \downarrow 9 pmol/L) and in patients withHbA1c >8% (\downarrow 0.5%, 1 \downarrow 0.7 pmol/L)

Khodaeian et al, Eur J Clin Invest 2015, Xu et al, PloS ONE, 2014

Vitamin E SIDE EFFECTS: Effect of long-term, high dose supplementation uncertain Potential adverse effects include hemorrhagic toxicity and diminished blood coagulations in patients who are also Vit K compromised High dose supplementation >400 IU ↑ risk of all cause mortality* CLINICAL IMPLICATIONS: Risk benefit would suggest little promise Potential for some benefit in patients with low vitamin E status or who are in poor control (HbA1c >8%)

Institute of Medicine 2006, Khodaeian et al, Eur J Clin Invest 2015, Xu et al, PloS ONE, 2014, * Miller et al, Ann Intern Med, 2005



Vitamin C


SIDE EFFECTS:

- ▶ High Dose Vit C generally considered safe
- ▶ Sudden increases in vitamin C can cause osmotic diarrhea & promote renal excretion
- ▶ High doses not recommended for individuals with renal stones, hyperoxaluria, or with compromised renal function (may ↑ oxalate formation)

CLINICAL IMPLICATIONS:

- Patients with hyperglycemia have elevated Vit C requirements
- Some evidence high dose Vit C supplementation influences glycemic control
- ▶ Vit C may impact OxStress/endothelial function → serum concentration and dose needed
- for OxStress may be different than other functions)
 Prudent that patients with diabetes select diet high in fruits and vegetables

Institute of Medicine 2006, Khodaeian et al, Eur J Clin Invest 2015, Tabatabaei-Malazy Xu et al, J Pharm Pharm Sci, 2014, Will & Byers Nutr Rev 1996



Pandey et al, Biochemistry, 1998; Verma et al, J Am Coll Nutr, 1998

Vanadium

STUDIES:


-5 non-randomized trials (1995 - 2001) in patients with diabetes
 1 RCT in patients with impaired glucose tolerance (IGT) (2008)


DOSING: 75-150 mg/day *Vanadyl Sulfate (BID/TID) for 2 - 6 weeks


RESULTS:

- Improvement in HbA1c (0.3 1.0% ↓) and FPG (23 -34 mg/dL ↓) in patient with DM
 No effect of supplementation on insulin sensitivity in patients with IGT
- Decreased basal endogenous glucose production and enhanced skeletal muscle insulin sensitivity in patients (n=11) with poorly controlled diabetes (via euglycemic clamp)

Smith et al, OJM 2008, Cusi et al, J Clin Endocrinol Metab, 2001) Jacques-Camarena, Ann Nutr Metab 2008







Vitamin D


DOSING: protocols vary, i.e., 1000 IU/day to 50,000 IU/wk and influence of status for various durations



RESULTS:

- RCT in 275 patients with well-controlled T2DM found no benefit of supplementation on glycemic control except in patients with very low status (>12 ng/ml) who experienced significant reductions in HbA1c with supplementation. Similar results in meta-analyses of PreDM patients (10 trials) only those with low status (>20 ng/ml) experienced reductions in FPG (↓ 2 mg/dL) and HbA1c (↓ 1.0 mm/mol)
- Meta-analysis in patients with T2DM (23 trials; varying vitamin D status) found that only patients in poor control (HbA1-8%) had an improvement in FPG (↓ 6.5 mg/dL). Meta-analysis (642 patients with DW) found that supplementation reduced systolic (↓ 4.6 mmHg, Cl=7.7 -1.5) and diastolic (↓ 8.7 mmHg, Cl=3.5-1.4) blood pressure
- Evidence from smaller trials suggests vitamin D improves neuropathic symptoms ($\downarrow 50\%$) and reduces risk for retinopathy

George et al, Diabet Med 2012, Krul-Poel et al Diabetes Care 2015, Krul-Poel et al, Eur J Endocrinol 2017, Poolsup, 2015, de Paula et al, Sci Rep 2017, Shehab et al Med Princ Pract 2015, Lee & Chen Arch Intern Med 2008, Hermann et al Diabetes Care 2015



Vitamin D

SIDE EFFECTS.

- ► Toxicity rare → reported in literature as accidental overdose
- ▶ Symptoms due to hypercalcemia → fatigue, nausea, back pain, tissue calcification > A U-shape association between vitamin D and diabetic neuropathy identified (case-
- control) -> may be a narrow optimal vitamin D range for DM patients

CLINICAL IMPLICATIONS:

- Insufficient evidence to support routine vitamin D supplementation; evaluation of status (serum 25(OH)D) important in "at risk" patients
- Maintaining sufficient vitamin D status (>20-30 ng/mL) essential in all patients; may progress from PreDM to DM and visk of DM complications
- Future trials should include larger N's and account for changes in vitamin D status with supplementation

Larson-Meyer & Willis Curr Sports Med Rep 2010, Abbasi et al, J Nutr 2015, Grammatiki Rev Endocr Metab Disord 2017, Holick et al J Clin Endocrinol Metab 2011

Vitamin B12 FUNCTION: Blood formation & Neurological function

SOURCES: Foods of animal origin, B12-fortified-foods

- RDA Adults = 2.4 µg UL=None
- Advisable those > 50 yr meet needs with supplement B12 or fortified foods (atrophic gastritis)

PURPORTED FUNCTION IN DIABETES:

- Long-term treatment with metformin decreases B12 status
- ▶ B12 deficiency \uparrow s severity of peripheral neuropathy in DM patients and may be important in its management

Lu et al, PLoS One, 2014, Sun, Lai & Lu, Acta Neurol Taiwan, 2005

Vitamin B12

STUDIES:

- Meta-analysis (6 RCT) evaluating B12 status in patients treated with metformin vs. placebo Meta-analysis (7 RCT) of effect of supplementation with B complex vitamin (including cyanocobalamin) or methylcobalamin alone (dating 1954 - 2004) on pain, vibration perception thresholds, autonomic symptoms, electrophysiological measures ►
- Single-blind RCT (100 patients) evaluating B12 supplementation vs. nortriptyline (n=50 each) on treatment of painful diabetic neuropathy.
- DOSING: Oral or injection for 4 to 16 weeks

RESULTS:

- ▶ Metformin \downarrow s B12 status \rightarrow effect is dose & duration dependent
- B12 supplementation alone or with B vitamins had overall beneficial effect on neuropathy management but symptomatic relief (pain, paresthesia) greater than electrophysiological changes); many studies not good quality
- Parenteral B12 more affective than nortriptyline for symptomatic painful diabetic neuropathy; sublingual B12 as effective as neuromuscular injections
- Lu et al, PLoS One, 2014, Sun, Lai & Lu, Acta Neurol Taiwan, 2005, Talaei et al Int J Food Sci Nutr 2009

Vitamin B12

SIDE EFFECTS.

No adverse effects known from food or cyanocobalamin supplementation in healthy individuals

CLINICAL IMPLICATIONS:

- Monitor biochemical and clinical signs of B12 deficiency in patients taking metformin Serum B12 >220 pmol/L = deficiency
- Megoblastic anemia, weakness, fatigue, SOB, palpitations, neutropenia ▶ Prudent recommendation is for all patients with diabetes to take MVI containing B12 → more research needed on efficacy of B12 supplementation

Institute of Medicine 2006, Haeusler, Parry-Strong & Krebs, N Z Med J 2014, Lu et al, PLoS One, 2014, ADA, Diabetes Care 2017

Multivitamin

- PURPORTED FUNCTION IN DIABETES:
- Improve glycemic control, prevent diabetes complications



- STUDIES:
- Numerous human studies looked at MVI or combination of various vitamins
- ▶ A single-blind RCT in 96 T2DM patients supplemented with MVI or MVI plus zinc sulfate vs placebo for 4 months found reductions in blood glucose (\downarrow 6 mg/dL), HbA1c (\downarrow 0.91%), and improvement of lipid profile with MVI plus Zn supplementation
- Double-blind RCT in 130 T2DM patients found that MVI supplementation for 1 year reduced incidence of infections *(43% vs 73%)
- Open label, uncontrolled study in 10 patients found that high dose supplementation with folate, pyridoxine and B12 reduced symptoms of retinopathy

Valdés-Ramos et alEndocr Metab Immune Disord Drug Targets 2015, Gunasekara et al Diabetes Metab Syndr Obes 2011, Barringer et al Ann Int Med 2003, Smolek et al Clin Opthalmol 2013


To Summarize and Conclude.....


- MNT for diabetes management should ensure consumption of foods rich in magnesium, vitamin E, vitamin C and vitamin B12 and ensure vitamin D sufficiency through sun exposure, diet and/or supplementation
- Supplemental doses of chromium picolinate, magnesium, vitamin C, vitamin D and vitamin B12 may be beneficial (at least over short-term) for some patients with diabetes
 - Patients in poor glycemic control
 - Patients with low nutrient status.
- Some results suggest impact of certain vitamin & mineral supplements similar to alpha-glucosidase inhibitors & DPP-4 inhibits
- Practitioners should continue to follow the research on vitamin and mineral supplementation in diabetes management


Evaluation


Although there is some supportive evidence, many individual trials and Metaanalyses did not:

- Monitor/control for diet, exercise, lifestyle change, medication use
- Monitor/control for nutrient status (difficult for some nutrients)
- ► Evaluate T1DM or GDM → most of the studies on T2DM
- Perform sub-group analysis to determine which patients may benefit









Study or Subgroup Balarsingh 2005 Ble-Castillo 2005 Boshtam 2005	Mean -0.06	SD T	intal M				Mean Difference	Mean Difference
Ble-Castilo 2005	-0.06				ID Total	Weight	IV. Random, 95% Ci	IV. Random, 95% GI
		0.68	10 0	32 0.	83 9	11.3%	-0.38 [-1.07, 0.31]	
Boshtam 2005	0.95	1.12	13 -1	83	4 21	9.9%	2,78 [1.93, 3.63]	
	-0.48	3.2	50	1.5	.1 50	6.1%	1.02 [-0.42, 2.46]	
de Oliveira 2011	-0.06	3.05	25 -4	02 4	1 26	4.0%	-0.04 [-2.02, 1.94]	
Gazis 1999	0.1	2.9	23	0.3 3.	15 25	4.9%	-0.20 [-1.91, 1.51]	
Manzella 2001	-0.1	0.3	25 -	0.1 0	12 25	14.9%	0.00 [-0.14, 0.14]	
Paolisso 1993	-0.7	0.35	25	0.1 0	14 25		-0.80 (-1.01, -0.59)	•
Paolisso 2000	-0.5	0.35			1.5 20		-0.40 [-0.67, -0.13]	*
Park 2002	-5.1	5.4	48 -	4.9 4	1.3 50	4,1%	-0.20 [-2.14, 1.74]	
Reaven 1995	-0.04	2	10 -0	12 1.	87 11	5.1%	0.08 [-1.58, 1.74]	
Tutuncu 1998	0.5	2.1			12 10		0.10 [-1.74, 1.94]	
Ward 2007	0.1	2.7	37	0.1	14 18	6.2%	0.20[-1.21, 1.61]	-
Tetal (95% CI)			297		290	100.0%	0.12 [-0.34, 0.58]	+
Heterogeneity: Tau ⁴ = (0.36; CN	7 = 91.8	9, df = 1	1 (P <	0.00001);	1 = 88%		-4 -2 0 2 4
Test for overall effect: 2	Z = 0.52	(P=0.6	(0)				1	ours experimental Favours control
							ravi	ours experimental i Pavours control

